Here’s How Your Trade Atara Biotherapeutics Inc. (ATRA) Aggressively Right Now – News Heater
Home  »  Companies   »  Here’s How Your Trade Atara Biotherapeutics ...

Here’s How Your Trade Atara Biotherapeutics Inc. (ATRA) Aggressively Right Now

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Atara Biotherapeutics Inc. (NASDAQ:ATRA) went up by 0.44% from its latest closing price compared to the recent 1-year high of $28.20. The company’s stock price has collected 1.97% of gains in the last five trading sessions. Press Release reported on 11/08/21 that Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences

Is It Worth Investing in Atara Biotherapeutics Inc. (NASDAQ :ATRA) Right Now?

Plus, the 36-month beta value for ATRA is at 1.94. Opinions of the stock are interesting as 9 analysts out of 10 who provided ratings for Atara Biotherapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $33.00, which is $14.85 above the current price. ATRA currently public float of 87.96M and currently shorts hold a 12.32% ratio of that float. Today, the average trading volume of ATRA was 842.35K shares.

ATRA’s Market Performance

ATRA stocks went up by 1.97% for the week, with a monthly jump of 19.41% and a quarterly performance of 30.86%, while its annual performance rate touched -21.70%. The volatility ratio for the week stands at 4.44% while the volatility levels for the past 30 days are set at 5.56% for Atara Biotherapeutics Inc.. The simple moving average for the period of the last 20 days is 3.88% for ATRA stocks with a simple moving average of 19.57% for the last 200 days.

Analysts’ Opinion of ATRA

Many brokerage firms have already submitted their reports for ATRA stocks, with JP Morgan repeating the rating for ATRA by listing it as a “Overweight.” The predicted price for ATRA in the upcoming period, according to JP Morgan is $29 based on the research report published on May 13th of the current year 2021.

Citigroup, on the other hand, stated in their research note that they expect to see ATRA reach a price target of $27, previously predicting the price at $20. The rating they have provided for ATRA stocks is “Neutral” according to the report published on December 09th, 2020.

H.C. Wainwright gave a rating of “Buy” to ATRA, setting the target price at $31 in the report published on December 08th of the previous year.

ATRA Trading at 7.39% from the 50-Day Moving Average

After a stumble in the market that brought ATRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.64% of loss for the given period.

Volatility was left at 5.56%, however, over the last 30 days, the volatility rate increased by 4.44%, as shares surge +21.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.15% upper at present.

During the last 5 trading sessions, ATRA rose by +1.97%, which changed the moving average for the period of 200-days by -6.25% in comparison to the 20-day moving average, which settled at $17.63. In addition, Atara Biotherapeutics Inc. saw -7.54% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ATRA starting from Newell Joe, who sale 3,332 shares at the price of $17.12 back on Nov 16. After this action, Newell Joe now owns 113,097 shares of Atara Biotherapeutics Inc., valued at $57,034 using the latest closing price.

Touchon Pascal, the President and CEO of Atara Biotherapeutics Inc., sale 8,402 shares at $17.12 during a trade that took place back on Nov 16, which means that Touchon Pascal is holding 328,489 shares at $143,816 based on the most recent closing price.

Stock Fundamentals for ATRA

The total capital return value is set at -78.81, while invested capital returns managed to touch -78.55. Equity return is now at value -87.30, with -64.80 for asset returns.

Based on Atara Biotherapeutics Inc. (ATRA), the company’s capital structure generated 3.28 points at debt to equity in total, while total debt to capital is 3.18. Total debt to assets is 2.58, with long-term debt to equity ratio resting at 2.85. Finally, the long-term debt to capital ratio is 2.76.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 86.93, with the company’s debt to enterprise value settled at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.31.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Can Chewy Inc. (CHWY) Remain Competitive?

Chewy Inc. (NYSE:CHWY) went down by -5.02% from its latest closing price compared to the recent 1-year high of $120.00. The company’s stock price has

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam